会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • CELLULOSE DERIVATIVES FOR INHIBITING CRYSTALLIZATION OF POORLY WATER-SOLUBLE DRUGS
    • 用于抑制不溶性水溶性药物结晶的纤维素衍生物
    • WO2013106433A1
    • 2013-07-18
    • PCT/US2013/020835
    • 2013-01-09
    • VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.PERDUE RESEARCH FOUNDATION
    • EDGAR, Kevin, J.LI, BinTAYLOR, LynneILEVBARE, GraceWILLIAMS, Stephanie, M.LIU, Haoyu
    • A61K47/38A61K47/30A61K9/08A61K31/70
    • A61K47/38A61K9/146A61K31/05A61K31/352A61K31/357A61K31/40A61K31/427A61K31/536A61K31/70C08B3/00
    • The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the invention provide cellulose esters useful for inhibiting solution crystallization of drugs. Specific polymers of the invention include cellulose esters of formula (I) : wherein n of the ω-carboxyalkanoyl group, Formula (II), is 3, 4, 6, or 8 to provide a ω-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups; and wherein R is chosen from : a hydrogen atom; and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups; wherein there is a total degree of substitution of the alkanoyl group and the ω-carboxyalkanoyl group of at least 2.0; and wherein the polymer comprises m repeating units where n = 1 to 1,000,000, or 10 to 100,000, or 100 to 1,000, such as 1 to 6,000. Embodiments further include compositions comprising cellulose esters and poorly water-soluble drugs, which compositions exhibit greater solubility and stability in solution as compared to the drugs alone. Drugs that can be used in combination with such polymers include but are not limited to ritonavir, efavirenz, etravirine, celecoxib, clarithromycin, curcumin, ellagic acid, quercetin, naringenin, and resveratrol. Methods for making and using the compounds and compositions are also included within the scope of the invention.
    • 本发明涉及化学和药物领域。 本发明的实施方案提供了可用于抑制药物溶液结晶的纤维素酯。 本发明的具体聚合物包括式(I)的纤维素酯:其中式(II)的ω-羧基烷酰基中的n为3,4,6或8,以提供选自琥珀酰基,戊酰基, 己二酰基,癸二酰基和辛二酸基; 并且其中R选自:氢原子; 和选自乙酰基,丙酰基,丁酰基,戊酰基,己酰基,壬酰基,癸酰基,月桂酰基,棕榈酰基和硬脂酰基的烷酰基; 其中烷酰基和ω-羧基烷酰基的总取代度为至少2.0; 并且其中所述聚合物包含m个重复单元,其中n = 1至1,000,000,或10至100,000,或100至1,000,如1至6,000。 实施方案还包括包含纤维素酯和水溶性差的药物的组合物,与单独的药物相比,该组合物在溶液中表现出更大的溶解度和稳定性。 可以与这些聚合物组合使用的药物包括但不限于利托那韦,依法韦仑,依伐维林,塞来昔布,克拉霉素,姜黄素,鞣花酸,槲皮素,柚皮苷和白藜芦醇。 制备和使用化合物和组合物的方法也包括在本发明的范围内。
    • 10. 发明申请
    • USE OF BIOCOMPATIBLE POLYMERS FOR THE PREPARATION OF A COMPOSITION OR A MEDICAL DEVICE
    • 用于制备组合物或医疗设备的生物易燃聚合物的使用
    • WO2005041986A3
    • 2006-04-20
    • PCT/FR2004002780
    • 2004-10-28
    • OTR3 ORGANES TISSUS REGENERATIBARRITAULT DENISBARBIER-CHASSEFIERE VERONIQUE
    • BARRITAULT DENISBARBIER-CHASSEFIERE VERONIQUE
    • A61K31/737A61K31/795A61K47/36A61K47/42A61P17/02A61P29/00
    • C08B3/00A61K8/73A61K8/731A61K8/85A61K31/737A61K31/795A61Q19/00A61Q19/02C08B37/0009C08B37/0021C08G63/06
    • The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR' group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula -ROS03R' or -RNS03R' in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R' denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same. In addition, in certain cases, the use of said biocompatible polymers for pain treatment can impact on the actual curing of certain diseases. Significant improvements and even cures have been observed in relation to chronic and painful diseases that are associated with alterations in the extracellular matrix regardless of the origin thereof.
    • 本发明涉及具有通式(I)A a X x Y y的生物相容性聚合物,其中:A表示单体; X表示RCOOR'基团; Y表示固定在A上并具有式-ROS03R'或-RNS03R'的O或N-磺酸盐基团,其中R表示可含有一个或多个芳环的任选支链和/或不饱和脂族烃链,R '表示氢原子或阳离子; a表示单体数目; x表示X单体的A单体的取代率; y表示Y单体由Y基取代的比例。 更具体地,本发明涉及所述生物相容性聚合物用于制备药物,皮肤病学或化妆品组合物或医疗装置的用途,其旨在防止,缓解和/或治疗不适,痛苦,瘙痒,刺激和/或 疼痛和/或保护组织免受同样的影响。 此外,在某些情况下,使用所述生物相容性聚合物进行疼痛治疗可能会影响某些疾病的实际固化。 对于与细胞外基质的改变相关的慢性和疼痛性疾病,观察到显着的改善甚至治愈,不管其来源如何。